Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01504126 · ClinicalTrials.gov registry record · Early Phase 1
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT01504126: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01504126 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01504126, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This early phase I trial studies giving propranolol hydrochloride with standard chemotherapy in treating patients with ovarian, primary peritoneal, or fallopian tube cancer. Biological therapies, such as propranolol hydrochloride, blocks certain chemicals that affect the heart and this may stimulate the immune system and allow the chemotherapy to kill more tumor cells.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Chemotherapy
- PROCEDURE Therapeutic Conventional Surgery
- DRUG Propranolol Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-03-09 |
| Est. Completion | 2019-08-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01504126
The ClinicalTrials.gov registry entry for NCT01504126 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT01504126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01504126 about?
NCT01504126 is a clinical study titled "Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". This early phase I trial studies giving propranolol hydrochloride with standard chemotherapy in treating patients with ovarian, primary peritoneal, or fallopian tube cancer. Biological therapies, such as propranolol hydrochloride, blocks certain chemicals that affect the heart and this may stimulate...
What is the current status of trial NCT01504126?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2012-03-09. Estimated completion is 2019-08-15.
What interventions are being tested in trial NCT01504126?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Chemotherapy (DRUG), Therapeutic Conventional Surgery (PROCEDURE), Propranolol Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01504126?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.